RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount
RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
Class 1 Recalls & Food Safety—Why They’re More Common Than You Think
Class 1 recalls pose serious health risks, from undeclared allergens to bacterial contamination. Here’s how Class 1 recalls work, plus major FDA food recalls in 2025.
The American Journal of Managed Care21h
Brolucizumab Effective in Patients With Wet AMD, Regardless of Past Treatment
Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...